Nivolumab is a programmed cell death protein 1 (PD-1) inhibitor approved for the treatment of NSCLC, head and neck squamous cell carcinoma, and gastric cancer, among others. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.